[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, Bovée JV: The clinical approach towards chondrosarcoma. Oncologist; 2008 Mar;13(3):320-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical approach towards chondrosarcoma.
  • This review provides an overview of the histopathology, classification, diagnostic procedures, and therapy of skeletal chondrosarcoma.
  • Chondrosarcomas that arise de novo are primary chondrosarcomas, whereas chondrosarcomas developing superimposed on pre-existing benign cartilage neoplasms such as enchondromas or osteochondromas are referred to as secondary chondrosarcomas.
  • Rare subtypes of chondrosarcoma, including dedifferentiated, mesenchymal, and clear cell chondrosarcoma, are discussed as well.
  • Magnetic resonance imaging is necessary to delineate the extent of the intraosseous and soft tissue involvement preoperatively.
  • Computed tomography is especially recommended in the pelvis and other flat bones where it may be difficult to discern the pattern of bone destruction and the presence of matrix mineralization.
  • Wide, en-bloc excision is the preferred surgical treatment in intermediate- and high-grade chondrosarcoma.
  • In low-grade chondrosarcoma confined to the bone, extensive intralesional curettage followed by local adjuvant treatment and filling the cavity with bone graft has promising long-term clinical results and satisfactory local control.
  • Chondrosarcomas are relatively radiotherapy resistant; therefore, doses >60 Gy are needed in attempts to achieve local control after incomplete resection.
  • Chemotherapy is only possibly effective in mesenchymal chondrosarcoma, and is of uncertain value in dedifferentiated chondrosarcoma.
  • Potential new systemic treatment targets are being discussed.
  • [MeSH-major] Bone Neoplasms / therapy. Chondrosarcoma, Mesenchymal / therapy
  • [MeSH-minor] Humans. Mesoderm / pathology. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncologist. 2008 May;13(5):618
  • (PMID = 18378543.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 91
  •  go-up   go-down


2. Okada K, Hasegawa T, Tateishi U, Endo M, Itoi E: Dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features. J Clin Pathol; 2006 Nov;59(11):1200-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features.
  • A wide excision of the left proximal femur with a replacement by endoprosthesis was carried out in February 2001 after treatment with methotrexate and 20 Gy radiation therapy.
  • Pathological examination of the surgical specimen showed a focus of low-grade chondrosarcoma and the coexistence of telangiectatic osteosarcoma-like features.
  • The patient was diagnosed with dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features.
  • Lung metastasis appeared in July 2001 despite an adjuvant chemotherapy including methotrexate, cis-platinum and doxorubicin.
  • Establishing a definitive diagnosis of dedifferentiated chondrosarcoma may be difficult with limited small biopsy specimens.
  • Dedifferentiated chondrosarcoma should be included in the differential diagnosis of osteolytic tumours with focal calcification and endosteal scalloping even if an extraosseous tumour component is not identified.
  • [MeSH-major] Bone Neoplasms / diagnosis. Chondrosarcoma / diagnosis. Mixed Tumor, Malignant / diagnosis. Osteosarcoma / diagnosis
  • [MeSH-minor] Adult. Cell Differentiation. Femur. Humans. Lung Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 1999 Nov;31(4):428-30 [10643020.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):55-61 [10697315.001]
  • [Cites] Ann Diagn Pathol. 2002 Jun;6(3):159-63 [12089726.001]
  • [Cites] Cancer. 1971 Aug;28(2):461-6 [5566365.001]
  • [Cites] J Bone Joint Surg Am. 1986 Oct;68(8):1197-205 [3021775.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):293-8 [8772782.001]
  • [Cites] Cancer. 1976 Dec;38(6):2538-47 [1069603.001]
  • (PMID = 17071806.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860503
  •  go-up   go-down


3. Montella L, Addeo R, Faiola V, Cennamo G, Guarrasi R, Capasso E, Mamone R, Caraglia M, Del Prete S: Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. J Exp Clin Cancer Res; 2009;28:7
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports.
  • PATIENTS AND METHODS: Zoledronic acid was used in a 63-year-old man with metastatic chondrosarcoma and in a 66-year-old woman with a diagnosis of sacrum chordoma both reporting severe pain related to tumor.
  • RESULTS: In the first case, zoledronic acid was able to maintain pain control despite disease progression following chemotherapy, in the other case, zoledronic acid only produced significant clinical benefit.
  • CONCLUSION: Control of pain associated with bone tumors such as chondrosarcoma and chondroma may significantly improve from use of zoledronic acid, independently from tumor response to other treatments.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chondroma / drug therapy. Chondrosarcoma / drug therapy. Chondrosarcoma / secondary. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Sacrum / pathology. Spinal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2002 May;8(5):1080-4 [12006522.001]
  • [Cites] Oncologist. 2004;9 Suppl 4:3-13 [15459425.001]
  • [Cites] J Bone Miner Res. 1994 May;9(5):745-51 [8053405.001]
  • [Cites] Neurocirugia (Astur). 2005 Apr;16(2):169-72; discussion 172 [15915306.001]
  • [Cites] Bone. 2005 Jul;37(1):74-86 [15894525.001]
  • [Cites] Support Care Cancer. 2008 Feb;16(2):209-14 [17701225.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2522-9 [16270320.001]
  • [Cites] J Orthop Res. 2006 Jun;24(6):1145-52 [16602111.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):980-4 [16570273.001]
  • [Cites] Mol Pharmacol. 2007 Jan;71(1):333-43 [17050806.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):255-61 [17242698.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1713-20 [16121404.001]
  • (PMID = 19144109.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  • [Other-IDs] NLM/ PMC2631458
  •  go-up   go-down


Advertisement
4. Staals EL, Bacchini P, Mercuri M, Bertoni F: Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am; 2007 May;89(5):987-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dedifferentiated chondrosarcomas that arise in osteochondromas are extremely rare lesions for which very little information on treatment and outcome is available in the literature.
  • The purpose of the present study was to describe the specific clinical, radiographic, and histologic features of this lesion and to evaluate the oncologic outcome after different treatment strategies.
  • Radiographic studies, histologic slides, and clinical records were reviewed, the features of those studies were tabulated, and prognostic features and the results of treatment were identified.
  • Radiographically, ten lesions appeared as a conventional secondary chondrosarcoma arising in an exostosis, whereas eight showed typical signs of dedifferentiation.
  • For the fifteen patients who were managed at the authors' institution, the two and five-year survival rates were 47% and 29%, respectively; the median survival time was fourteen months.
  • Patients who were managed with a combination of surgery and chemotherapy had a better overall survival rate than did those who were managed with surgery alone (p = 0.03).
  • CONCLUSIONS: Dedifferentiated chondrosarcoma arising in a preexisting osteochondroma is an extremely rare lesion with a poor prognosis.
  • In the present small series, overall survival was better when wide surgical resection was combined with adjuvant chemotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Chondrosarcoma / pathology. Osteochondroma / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473135.001).
  • [ISSN] 0021-9355
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Shi SF, Dong Y, Zhang CL, Bao K, Ma XJ: [Prosthesis replacement of the proximal humerus after the resection of bone tumors]. Chin J Cancer; 2010 Jan;29(1):121-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: After chemotherapy was used to treat patients with malignant bone tumors in 1970s, amputation, which was the typical intervention in the 1980s, has been substituted with limb-sparing surgery.
  • METHODS: From April 2004 and December 2008, prosthetic replacement was performed in 18 patients with proximal humerus tumors, including 7 patients with osteosarcoma, 5 patients with chondrosarcoma, 3 patients with giant cell tumor (GCT) of the bone, 1 patient with GCT of the bone combined with an aneurysmal bone cyst, and 1 patient with metastatic bone tumors.
  • According to the functional score developed by the International Society of Limb Salvage, scores ranged between 18 and 29 points, with an average of 24 points.
  • CONCLUSIONS: The prosthesis replacement for the patients with bone tumors in the proximal humerus is an appropriate procedure with satisfactory therapeutic outcomes; however, many complications should be noted and long-term therapeutic effect needs further investigations.
  • [MeSH-major] Bone Neoplasms / surgery. Chondrosarcoma / surgery. Humerus. Osteosarcoma / surgery. Prosthesis Implantation
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement. Female. Follow-Up Studies. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / radiography. Giant Cell Tumor of Bone / surgery. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Range of Motion, Articular. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038324.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Vukasinović Z, Spasovski D, Slavković N, Slavković S, Zivković Z: [Chondroblastoma--current opinion]. Srp Arh Celok Lek; 2006 Nov-Dec;134(11-12):567-70
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is considered a benign lesion, although primary malignant form as well as malignant alteration in the form of chondrosarcoma has been documented.
  • Pathohistologically, it is described as highly cellular tissue, variably differentiated and with discrete granulated to meshy calcification of the matrix and large multinuclear cells present in 20% of cases.
  • Secondary formation of aneurysmal bone cyst has been documented.
  • Tumor is presented with a few nonspecific local symptoms, which makes diagnostic procedure more difficult.
  • Definitive diagnosis is made only by pathohistological verification.
  • The treatment of chondroblastoma is strictly surgical, with a view to counteract the propagation into the joint or adjacent soft tissue, and diminish the recurrence rate.
  • Chemotherapy is not indicated for treatment of this tumor, and radiotherapy is contraindicated as it stimulates malignant alteration.
  • If malignant chondroblastoma of bone is verified pathohistologically, radical treatment by surgical resection is indicated, also avoiding any adjuvant therapy.

  • Genetic Alliance. consumer health - Chondroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304775.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia and Montenegro
  • [Number-of-references] 34
  •  go-up   go-down


7. Lin JR, Zhang WM, Wang ZC: Primary malignant bone neoplasm: a case report of dedifferentiated chondrosarcoma in the rib and review of the literature. Chin J Cancer; 2010 Nov;29(11):964-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant bone neoplasm: a case report of dedifferentiated chondrosarcoma in the rib and review of the literature.
  • Dedifferentiated chondrosarcoma (DDCS) is a rare but highly malignant primary bone neoplasm, which is resistant to radiotherapy and chemotherapy.
  • There remains uncertainly as to the best treatment of this disease and how to improve its prognosis.
  • In this paper we reported a case of DDCS and reviewed the related literatures in order to provide references to throw a light on the histogenesis, diagnosis and therapy of this disease.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Chondrosarcoma / radionuclide imaging. Hemangioendothelioma / secondary. Lung Neoplasms / secondary. Ribs
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Follow-Up Studies. Humans. Immunohistochemistry. Male. Methotrexate / administration & dosage. Multimodal Imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979697.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. McGrory JE, Rock MG, Nascimento AG, Oliveira AM: Extraskeletal myxoid chondrosarcoma. Clin Orthop Relat Res; 2001 Jan;(382):185-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal myxoid chondrosarcoma.
  • The medical records and histologic material of 16 patients with extraskeletal myxoid chondrosarcoma were reviewed.
  • Treatment of the primary site included wide excision or amputation in 13 patients and marginal or intralesional resections with radiation in three patients.
  • Local recurrence developed in four, and metastases developed in six of 13 patients presenting with localized disease.
  • Of six patients who received chemotherapy for systemic disease, four had disease progression and died, and two had a response to chemotherapy (one partial, one complete).
  • The current series suggests that extraskeletal myxoid chondrosarcoma is an intermediate-grade neoplasm with a tendency toward recurrence and metastasis.
  • More effective therapy for systemic disease is needed.
  • [MeSH-major] Chondrosarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Amputation. Chemotherapy, Adjuvant. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Leg / surgery. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11153986.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Mohammadinezhad C: Chondrosarcoma of the jaw. J Craniofac Surg; 2009 Nov;20(6):2097-100
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondrosarcoma of the jaw.
  • Chondrosarcoma of the maxillofacial region is a rare tumor.
  • Recently, molecular and genomic studies thought to be useful tools in a more definite diagnosis, accurate treatment, and quality of life of patients.
  • The most acceptable choice of treatment of the chondrosarcoma is wide resection.
  • Radiotherapy and chemotherapy as an adjunctive or palliative treatment remain controversial.
  • However, lifelong follow-up is essential because chondrosarcoma shows a high incidence of local recurrence as well as regional and distant metastasis more than 2 decades later.
  • This study presents 2 cases of chondrosarcoma with a long-term follow-up.
  • [MeSH-major] Chondrosarcoma / pathology. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Nose. Orbital Implants. Prostheses and Implants. Skull Base Neoplasms / secondary. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881362.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Demura Y, Saito H, Yashiki N: [Chondrosarcoma of the rib with pleural dissemination]. Kyobu Geka; 2009 May;62(5):399-403
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chondrosarcoma of the rib with pleural dissemination].
  • Chest computed tomography (CT) showed a 10.0 x 6.6 cm mass arising from the left chest wall.
  • The diagnosis of grade II chondrosarcoma was made with CT guided percutaneous needle biopsy.
  • Adjuvant chemotherapy using OK-432, carboplatin and etoposide was tried as treatment for pleural dissemination.
  • Radical excision of chondrosarcoma of the rib including all pleural dissemination is difficult.
  • Multidisciplinary approach including resection of a primary tumor has potential to improve prognosis in some cell types.
  • And long term follow-up is necessary to determine effectiveness of adjuvant chemotherapy in this case.
  • [MeSH-major] Chondrosarcoma / pathology. Neoplasm Seeding. Pleural Neoplasms / secondary. Ribs. Thoracic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19425383.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Takeda A, Tsuchiya H, Mori Y, Nonomura A, Tomita K: Extraskeletal myxoid chondrosarcoma with multiple skeletal metastases. J Orthop Sci; 2000;5(2):171-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal myxoid chondrosarcoma with multiple skeletal metastases.
  • Pulmonary metastases are not unusual in extraskeletal myxoid chondrosarcoma; however, only two patients have been reported with multiple bony metastases.
  • We report here one patient with extraskeletal myxoid chondrosarcoma associated with lung and multiple bony metastases.
  • After chemotherapy, the primary lesion was resected, but lung and multiple bony metastases were found 20 months later.
  • After chemotherapy, the lung metastases were resected, and those in the vertebral bodies were treated with radiotherapy.
  • [MeSH-major] Bone Neoplasms / secondary. Chondrosarcoma / secondary. Lung Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / secondary. Femoral Neoplasms / therapy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10982652.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


12. Keskin EY, Gursel T, Uluoglu O, Albayrak M, Kaya Z, Coskun U, Kocak U: Parathyroid adenoma and chondrosarcoma after treatment of pediatric Hodgkin disease. J Pediatr Hematol Oncol; 2010 Oct;32(7):e294-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid adenoma and chondrosarcoma after treatment of pediatric Hodgkin disease.
  • Treatment of Hodgkin disease (HD) with chemoradiotherapy in children is associated with increased risk for developing secondary neoplasms.
  • Parathyroid adenoma (PTA) and chondrosarcoma (CS) are quite rare types of secondary neoplasms after HD.
  • We describe a 5-year-old boy with stage IV HD, successfully treated with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)/ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy followed by 35 Gy mantle radiotherapy who developed primary hyperparathyroidism because of benign PTA at the age of 20 years, and died of CS in thoracic vertebrae at the age of 22 years.
  • Consecutive occurrence of PTA and CS after treatment of pediatric HD, to the best of our knowledge, has not been reported earlier.
  • [MeSH-major] Adenoma / diagnosis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chondrosarcoma / diagnosis. Hodgkin Disease / drug therapy. Neoplasms, Second Primary / diagnosis. Parathyroid Neoplasms / diagnosis
  • [MeSH-minor] Bleomycin / therapeutic use. Child, Preschool. Combined Modality Therapy. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Humans. Hyperparathyroidism, Primary / diagnosis. Male. Mechlorethamine / therapeutic use. Prednisone / therapeutic use. Procarbazine / therapeutic use. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736843.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


13. Akahane T, Shimizu T, Isobe K, Yoshimura Y, Kato H: Dedifferentiated chondrosarcoma arising in a solitary osteochondroma with leiomyosarcomatous component: a case report. Arch Orthop Trauma Surg; 2008 Sep;128(9):951-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated chondrosarcoma arising in a solitary osteochondroma with leiomyosarcomatous component: a case report.
  • BACKGROUND: A rare variant of dedifferentiated chondrosarcoma with leiomyosarcomatous component in a 63-year-old male is reported.
  • CASE REPORT: He had a life-long osteochondroma adjacent to the left knee and recently developed swollen and pain.
  • We initially suspected an intermediate grade chondrosarcoma arising in a solitary osteochondroma, but a biopsy specimen revealed a dedifferentiated component that histologically was classified as leiomyosarcoma.
  • The patient underwent amputation above knee and lung operation following adjuvant chemotherapy, but he died because of pulmonary metastasis 2 years after first admission.
  • [MeSH-major] Chondrosarcoma / pathology. Femoral Neoplasms / pathology. Leiomyosarcoma / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Humans. Lung Neoplasms / secondary. Male. Middle Aged

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Genetic Alliance. consumer health - Osteochondroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196252.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Debruyne PR, Dumez H, Demey W, Gillis L, Sciot R, Schöffski P: Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide. Onkologie; 2007 Apr;30(4):201-4
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide.
  • BACKGROUND: Low- to intermediate-grade chondrosarcoma is usually a slow-growing and highly chemotherapyresistant tumor type.
  • CASE REPORT: The 76-year-old female patient presented with low- to intermediate-grade chondrosarcoma of the distal phalanx of the right thumb in 1993 and was treated with an excision of the carpometacarpal joint.
  • A follow-up CT scan after 8 months demonstrated a partial remission that was confirmed by a second scan after 9 months of treatment.
  • The treatment was well tolerated.
  • After 18 months of continued treatment, she was still in remission and on trofosfamide.
  • CONCLUSION: Trofosfamide at a daily dose of 150 mg may be effective in low- to intermediate-grade chondrosarcoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Bone Neoplasms / drug therapy. Carpometacarpal Joints. Chondrosarcoma / secondary. Cyclophosphamide / analogs & derivatives. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy. Thumb
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17396043.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; H64JRU6GJ0 / trofosfamide
  •  go-up   go-down


15. Verdegaal SH, Corver WE, Hogendoorn PC, Taminiau AH: The cytotoxic effect of phenol and ethanol on the chondrosarcoma-derived cell line OUMS-27: an in vitro experiment. J Bone Joint Surg Br; 2008 Nov;90(11):1528-32
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cytotoxic effect of phenol and ethanol on the chondrosarcoma-derived cell line OUMS-27: an in vitro experiment.
  • Surgery is considered to be the most effective treatment for cartilaginous tumours.
  • In recent years, a trend has emerged for patients with low-grade tumours to be treated less invasively using curettage followed by various forms of adjuvant therapy.
  • Using a human chondrosarcoma-derived cartilage-producing cell line OUMS-27 as an in vitro model we studied the cytotoxic effect of phenol and ethanol.
  • Since ethanol is the standard substance used to rinse phenol out of a bone cavity, we included an assessment of ethanol to see whether this was an important secondary factor with respect to cell death.
  • These results may provide a clinical rationale for the use of both phenol and ethanol as adjuvant therapy after intralesional curettage in low-grade central chondrosarcoma and justify further investigation.
  • [MeSH-major] Chondrosarcoma / drug therapy. Cytotoxins / therapeutic use. Ethanol / therapeutic use. Phenol / therapeutic use
  • [MeSH-minor] Cell Line. Chemotherapy, Adjuvant. Curettage. Humans. Statistics as Topic

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Hazardous Substances Data Bank. PHENOL .
  • Hazardous Substances Data Bank. SODIUM PHENOLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978278.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytotoxins; 339NCG44TV / Phenol; 3K9958V90M / Ethanol
  •  go-up   go-down


16. Gadwal SR, Fanburg-Smith JC, Gannon FH, Thompson LD: Primary chondrosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 14 cases with a review of the literature. Cancer; 2000 May 1;88(9):2181-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chondrosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 14 cases with a review of the literature.
  • BACKGROUND: Primary chondrosarcoma of the head and neck in the pediatric age group is rare.
  • METHODS: Fourteen cases of chondrosarcoma of the head and neck from patients age 18 years or younger, diagnosed between 1970 and 1997, were retrieved from the Otorhinolaryngic-Head & Neck Tumor Registry of the Armed Forces Institute of Pathology.
  • No secondary sarcomas (radiation-induced or arising in association with Maffucci syndrome or Ollier disease) were included.
  • All patients were treated by surgery, followed by radiation (n=5) and/or chemotherapy (n=2).
  • CONCLUSIONS: Primary head and neck chondrosarcoma in the pediatric population is typically low grade and occurs in the maxillary sinus or mandible.
  • [MeSH-major] Chondrosarcoma / pathology. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Headache / diagnosis. Humans. Male. Mandibular Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Nasal Obstruction / diagnosis. Neoplasm Invasiveness. Nose Neoplasms / pathology. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhinitis / diagnosis. Sinusitis / diagnosis

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813732.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 41
  •  go-up   go-down


17. Tanigawa M, Kimura M, Ichioka M, Saito K, Kimura M: [A case of true pulmonary carcinosarcoma]. Nihon Kokyuki Gakkai Zasshi; 2003 Jul;41(7):496-501
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The resected tumor was composed of adenocarcinomatous and sarcomatous components, including partially-differentiated chondrosarcoma and rhabdomyosarcoma.
  • Nevertheless, chemotherapy, linac radiosurgery, percutaneous radiofrequency ablation, and partial small intestinal resection combined with rectal resection were performed.
  • Liver metastatic lesions were determined to be the adenocarcinomatous component, and the other recurrent or metastatic lesions, except for those in the brain, were all composed of poorly-differentiated sarcomatous tissue.
  • [MeSH-minor] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Chondrosarcoma / pathology. Humans. Intestinal Neoplasms / secondary. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931680.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Sato S, Koike T, Yamato Y, Yoshiya K, Motono N, Takeshige M, Homma K, Koizumi N, Yokoyama A, Tsukada H: A case of rapidly growing pulmonary carcinosarcoma. Int J Clin Oncol; 2010 Jun;15(3):319-24
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest computed tomography (CT) found a 2.0 cm pulmonary mass with suspected chest wall invasion in the right upper lobe, although cytological evidence of malignancy could not be obtained despite repeated preoperative bronchoscopy.
  • The postoperative definitive diagnosis was carcinosarcoma consisting of adenocarcinoma and chondrosarcoma.
  • The patient subsequently received adjuvant chemotherapy with cisplatin and vinorelbine.
  • Consequently he underwent radiotherapy, but the disseminated tumors enlarged further while he received this treatment.
  • Findings based on previously reported cases and our case suggest that early surgical intervention and combined therapeutic strategy are the most important aspects of treatment for pulmonary carcinosarcoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinosarcoma / pathology. Chondrosarcoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchoscopy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease Progression. Humans. Male. Neoplasm Staging. Pleural Neoplasms / radiotherapy. Pleural Neoplasms / secondary. Pneumonectomy. Tomography, X-Ray Computed. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Mol Pathol. 2008 Sep;17(3):151-8 [18382357.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1514-26 [10584705.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):277-85 [8772780.001]
  • [Cites] Semin Diagn Pathol. 1993 May;10(2):118-27 [8367621.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3893-7 [17094419.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Apr;23(4):461-6 [12694760.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):510-6 [11914631.001]
  • [Cites] Am J Clin Pathol. 1982 Feb;77(2):123-36 [7064914.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):691-4 [9275879.001]
  • [Cites] Eur J Cardiothorac Surg. 1996;10(6):403-7 [8817133.001]
  • [Cites] Ann Thorac Surg. 2007 Sep;84(3):973-80 [17720411.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Sep;134(3):619-23 [17723808.001]
  • [Cites] Br J Dis Chest. 1985 Jan;79(1):83-94 [3986115.001]
  • [Cites] Mayo Clin Proc. 1984 Sep;59(9):598-603 [6381913.001]
  • (PMID = 20217450.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


19. Pandya NK, Auerbach JD, Baldwin K, Lackman RD, Chin KR: Spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine: case report. Spine (Phila Pa 1976); 2006 Nov 15;31(24):E920-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: When faced with a patient with a history of multiple hereditary exostoses with new onset of myelopathic symptoms and a mass compressing the spinal cord, the clinician's differential should be broad and always initially include a metastatic lesion, osteochondroma, or chondrosarcoma.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / diagnosis. Exostoses, Multiple Hereditary / complications. Neoplasms, Unknown Primary / diagnosis. Spinal Cord Compression / etiology. Spinal Neoplasms / secondary. Thoracic Vertebrae / surgery
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chondrosarcoma / diagnosis. Combined Modality Therapy. Decompression, Surgical. Diagnosis, Differential. Female. Humans. Laminectomy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Paclitaxel / administration & dosage. Spinal Fusion. Tomography, X-Ray Computed. Trastuzumab


20. Fu M, Shen JN, Huang G, Wang J, Fu QZ, Yang ZH: [Reconstruction of the hemipelvis with saddle prosthesis after excision of malignant tumors around the pelvis and acetabulum: a report of 12 cases]. Ai Zheng; 2007 Nov;26(11):1237-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The characteristics of the operating for this disease were analyzed in terms of preoperative preparation, operating strategy, prosthesis design, operating procedure, acetabular reconstruction, and postoperative rehabilitation.
  • Of the 4 patients with tumor relapse, 2 osteosarcoma patients died of lung metastasis at 15 months and 22 months after operation; 1 chondrosarcoma patient relapsed locally at 26 months after operation and died at 38 months after operation; 1 giant cell tumor patient relapsed locally at 13 months after operation and was treated by clearance of focal lesion, and survived tumor-freely till the end of follow-up.
  • For bone tumors with relatively low malignancy, this surgical treatment is an ideal option.
  • [MeSH-major] Acetabulum / surgery. Arthroplasty, Replacement, Hip / methods. Bone Neoplasms / surgery. Chondrosarcoma / surgery. Hip Prosthesis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Osteosarcoma / drug therapy. Osteosarcoma / secondary. Osteosarcoma / surgery. Pelvic Bones / surgery. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991325.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


21. Ferrandina G, Zannoni GF, Martinelli E, Vellone V, Prisco MG, Scambia G: Endometrial carcinoma recurring as carcinosarcoma: report of two cases. Pathol Res Pract; 2007;203(9):677-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1. a 58-year-old postmenopausal woman diagnosed to have a poorly differentiated endometrial endometrioid adenocarcinoma (FIGO stage IB) developed an intra-abdominal recurrence of disease after 17 months from diagnosis.
  • Salvage chemotherapy with cisplatin, ifosfamide, epirubicin, and then with taxotere was attempted.
  • A 56-year-old woman with a diagnosis of grade 3 endometrial adenosquamous carcinoma of the endometrium (FIGO stage IIIA) experienced pelvic recurrence after five months from completion of chemotherapy.
  • Definitive histology was malignant mixed mesodermal tumor with focal areas of chondrosarcomatous elements.
  • The patient was triaged to exclusive concomitant chemoradiotherapy and salvage chemotherapy.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Endometrioid / secondary. Carcinosarcoma / secondary. Chondrosarcoma / secondary. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646054.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


22. Lewandrowski KU, Hecht AC, DeLaney TF, Chapman PA, Hornicek FJ, Pedlow FX: Anterior spinal arthrodesis with structural cortical allografts and instrumentation for spine tumor surgery. Spine (Phila Pa 1976); 2004 May 15;29(10):1150-8; discussion 1159
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the results following the use of cortical allografts in the treatment of spine tumors.
  • Controversy as to the appropriate type of anterior reconstruction and/or graft material persists.
  • Ninety-three percent of all allografts were radiographically incorporated as early as 6 months after surgery in spite of adjuvant chemotherapy and radiation therapy.
  • [MeSH-minor] Adolescent. Adult. Aged. Braces. Carcinoma / drug therapy. Carcinoma / radiotherapy. Carcinoma / secondary. Carcinoma / surgery. Chemotherapy, Adjuvant. Chondrosarcoma / radiotherapy. Chondrosarcoma / surgery. Chordoma / radiotherapy. Chordoma / surgery. Combined Modality Therapy. Female. Humans. Intraoperative Complications / epidemiology. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Osteosarcoma / radiotherapy. Osteosarcoma / surgery. Postoperative Complications / epidemiology. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15131446.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR45062
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


23. Sagar TG, Chandra A, Raman SG, Swaminathan R: Paucity of hematological neoplasia after treatment of Hodgkin disease: observation after long-term follow-up at Cancer Institute, Chennai, south India. Pediatr Hematol Oncol; 2002 Apr-May;19(3):197-203
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paucity of hematological neoplasia after treatment of Hodgkin disease: observation after long-term follow-up at Cancer Institute, Chennai, south India.
  • The purpose of the study was to evaluate the incidence of second malignancies in childhood Hodgkin disease treated with COPP and COPP/ABV (replacing mechlorethamine by cyclophosphamide) chemotherapy.
  • All 5 were solid tumors: one each of soft tissue sarcoma, dermatofibrosarcoma, micropapillary carcinoma of thyroid, malignant phylloides tumor of breast, and chondrosarcoma of ilium.
  • All patients had received combination chemotherapy and radiotherapy.
  • All these patients had advanced stage of cancer and were 7-14 years of age at the time of diagnosis of first primary Hodgkin disease.
  • It is significant that there were no secondary hematological malignancies.
  • COPP and COPP/ABV are effective therapeutic regimens.
  • The paucity of secondary hematological malignancies is unique in this series and may be attributed to the substitution of nitrogen mustard with cyclophosphamide in the chemotherapy combination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hematologic Neoplasms / chemically induced. Hodgkin Disease / drug therapy
  • [MeSH-minor] Bleomycin / administration & dosage. Child, Preschool. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / prevention & control. Prednisone / administration & dosage. Procarbazine / administration & dosage. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11936733.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CVPPABO protocol
  •  go-up   go-down


24. Bramwell VH: Osteosarcomas and other cancers of bone. Curr Opin Oncol; 2000 Jul;12(4):330-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Experiments in animal models provide preliminary data on the feasibility of gene therapy in osteosarcoma and chondrosarcoma.
  • Prediction of response to chemotherapy remains a major focus of imaging research.
  • Several clinicopathologic studies have explored the mechanisms underlying multidrug resistance in osteosarcoma patients receiving neoadjuvant chemotherapy.
  • HER2/erbB2 expression, linked to poor prognosis, has been proposed as a therapeutic target in osteosarcoma.
  • Recent evidence confirms that secondary osteosarcomas and malignant fibrous histiocytomas of bone should be treated with aggressive chemotherapy regimens, similar to those used for osteosarcomas.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10888418.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 50
  •  go-up   go-down


25. Salamanca J, Dhimes P, Pinedo F, Gómez de la Fuente E, Pérez Espejo G, Martínez-Tello FJ: Extraskeletal cutaneous chondroblastic osteosarcoma: a case report. J Cutan Pathol; 2008 Feb;35(2):231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extraskeletal osteosarcoma is an uncommon neoplasm that usually arises in the deep soft tissues, especially in the lower extremities, with rare cases involving the subcutis or dermis.
  • The patient underwent postoperative chemotherapy and is currently alive with pulmonary metastases 15 months after surgery.
  • As a rule, when an obviously malignant 'chondrosarcoma' is identified, one should always consider this entity.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Thigh / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190451.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


26. Karnak I, Emin Senocak M, Kutluk T, Tanyel FC, Büyükpamukçu N: Pulmonary metastases in children: an analysis of surgical spectrum. Eur J Pediatr Surg; 2002 Jun;12(3):151-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary surgery is frequently used for the treatment of metastasis or nodules in children with various types of malignancies.
  • The primaries were osteosarcoma (n = 2), synovial sarcoma (n = 1), fibrosarcoma (n = 1), Ewing's sarcoma (n = 2), mesenchymal chondrosarcoma (n = 1), Wilms' tumour (n = 4), clear-cell sarcoma (n = 1), Hodgkin lymphoma (n = 3), hepatoblastoma (n = 1), hepatocellular carcinoma (n = 1) and haemangioendotheliosarcoma (n = 1).
  • Pulmonary metastases were encountered either at the time of initial diagnosis (22 %) or occurred within 6 months to 5 years.
  • The nodules contained tumour cells in most cases (n = 14) (78 %), mature nephrogenic elements (6 %) and no tumour tissue (16 %) in the remaining cases.
  • Therefore combined therapies such as chemotherapy and/or radiotherapy should be continued in the postoperative period.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Pneumonectomy. Retrospective Studies. Thoracotomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12101495.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Weber K, Damron TA, Frassica FJ, Sim FH: Malignant bone tumors. Instr Course Lect; 2008;57:673-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant bone tumors represent a small percentage of cancers nationwide and also are much less common than malignant soft-tissue tumors.
  • The rarity of the condition makes it imperative that orthopaedic surgeons in nononcologic practices are able to recognize the symptoms that suggest a possible bony malignancy to avoid inappropriate or delayed treatment.
  • Chondrosarcoma occurs more frequently in older adults.
  • Knowledge of specific tumor characteristics and treatment options for osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, chordoma, and adamantinoma is important.
  • Patients with osteosarcoma and resectable Ewing's sarcoma are treated with chemotherapy followed by surgical resection.
  • Secondary sarcomas can occur in previously benign bone lesions and require aggressive treatment.
  • The care of patients with primary malignant bone tumors requires a multidisciplinary approach to treatment.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399615.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


28. Aydinli U, Ozturk C, Yalcinkaya U, Tirelioglu O, Ersozlu S: Limb-sparing surgery for primary malignant tumours of the pelvis. Acta Orthop Belg; 2004 Oct;70(5):417-22
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of malignant tumours of the pelvis represents one of the most difficult problems in musculoskeletal oncology.
  • Wound complication was the most common complication in our series, with 10 patients requiring additional treatment in the form of local surgical debridement, appropriate multi-drug antimicrobial therapy and wound care.
  • Secondary pelvic reconstruction was performed in two patients with chondrosarcoma, due to local recurrence.
  • Major blood loss and long operation time, aggressive radical surgery due to the frequent delay in diagnosis, and wound complications after surgery are important points that should be considered in the treatment of primary malignant pelvic tumours.
  • [MeSH-minor] Adult. Angiography. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Reconstructive Surgical Procedures / methods. Retrospective Studies. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15587029.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


29. Rawlins JM, Batchelor AG, Liddington MI, Towns G: Tumor excision and reconstruction of the upper cervical spine: a multidisciplinary approach. Plast Reconstr Surg; 2004 Nov;114(6):1534-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Axis, Cervical Vertebra / surgery. Cervical Atlas / surgery. Chondrosarcoma / surgery. Chordoma / surgery. Cranial Fossa, Posterior / surgery. Osteosarcoma / surgery. Patient Care Team. Skull Base Neoplasms / surgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Transplantation. Chemotherapy, Adjuvant. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Female. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / radiotherapy. Femoral Neoplasms / surgery. Humans. Ifosfamide / administration & dosage. Interdisciplinary Communication. Internal Fixators. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Methotrexate / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Palliative Care. Protons / therapeutic use. Remission Induction. Spinal Fusion. Surgical Flaps

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15509945.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement